Avalon Pharma to localize Durvalumab production in Saudi Arabia

Middle East Pharmaceutical Industries (Avalon Pharma) has announced the signing of a strategic and exclusive agreement with Bio-THERA Solutions to localize the manufacturing of the drug "Dupilumab" in the Kingdom of Saudi Arabia and the Middle East and North Africa region. The agreement includes the registration and marketing of the drug, which is used to treat chronic inflammatory diseases such as asthma and atopic dermatitis. The goal is to achieve cumulative revenues of up to 400 million SAR during the first seven years following its planned launch in 2031. Under the collaboration, the Chinese company will be responsible for developing and manufacturing the product, while Avalon Pharma will handle regulatory approvals and marketing, with future prospects for technology transfer and local production within the Kingdom. This agreement represents a significant step towards strengthening the biopharmaceutical industry and enhancing the company's position in the regional market, in line with Saudi Arabia’s Vision 2030.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل